MétaCan
Menu
Back to cohort
Record W4410303297 · doi:10.1080/1750743x.2025.2493039

Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary

2025· article· en· W4410303297 on OpenAlexaboutno aff
Marc Schmalzing, H Kellner, Ayman Askari, Javier de Toro Santos, Julio Cesar Vazquez Perez-Coleman, Rosario Foti, Sławomir Jeka, Yannick Allanore, P. Peichl, Martin Oehri, Neil Betteridge, Cristofer Salvati, Elisa Isabel Sánchez-Romero, Ines Brueckmann, Tom Sheeran

Bibliographic record

VenueImmunotherapy · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBiosimilars and Bioanalytical Methods
Canadian institutionsnot available
FundersMedacCilagMylanCelgeneBiogenGilead SciencesChugai PharmaceuticalCelltrionSanofiEli Lilly and CompanyAstraZenecaEdwards LifesciencesAmgen
KeywordsBiosimilarEtanerceptMedicinePlain languagePharmacologyInternal medicineIntensive care medicineOncologyPhysical therapyRheumatoid arthritisLinguistics

Abstract

fetched live from OpenAlex

Plain Language SummaryWhat is this summary about?This summary explains the findings of a clinical study called COMPACT, which included people treated with a medicine called SDZ ETN. In the COMPACT study, 1466 people from Europe and Canada were treated with an etanercept biosimilar medicine called Sandoz-etanercept (called SDZ ETN in this summary and sold under the brand name ErelziTM). The COMPACT study included people with three different rheumatic diseases that commonly affect the joints or the spine, but can also impact various organs, such as the skin and heart. These were rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis.What are the key takeaways?People experienced consistent treatment benefits, defined as improvements in the signs and symptoms of their disease when treated with SDZ ETN over 12 months. There were no new side effects with SDZ ETN in this study.What were the main conclusions reported by the researchers?The results of the real-world COMPACT study support the safe and effective use of SDZ ETN in people with rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis in everyday settings.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.107
Threshold uncertainty score0.987

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.357
Teacher spread0.334 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueImmunotherapySame topicBiosimilars and Bioanalytical MethodsFrench-language works237,207